Few biopharma risers stand out at the half year
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Are we there yet?
Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.
First-quarter biotech risers work hard for the win
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
Outside big pharma, life remains tough for listed developers
A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.
Biopharma’s stock market winners of 2021 revealed
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
Diabetes device makers lead the smaller medtechs
Insulin pumps and glucose sensors flew off the shelves, whereas liquid biopsy developers both soared and sank.
Big beasts drive biopharma valuations higher in 2021
A handful of huge success stories mask disappointing performances elsewhere, with small caps and Asian pharma firms feeling the pain.
A bad year to be an American medtech
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.